中国药业Issue(8)：14-17,4.
奥美沙坦对高血压患者血压晨峰管理和靶器官保护的临床研究﹡
Clinical Efficacy of Olmesartan on Morning Blood Pressure Surge Management and Target Organ Protection in Hypertensive Patients
摘要
Abstract
Objective To investigate the effects of olmesartan and amlodipine on morning blood pressure surge(MBPS)measurement and the target organ protection in hypertension. Methods 103 primary hypertension patients with MBPS were randomly divided into the two groups and treated by olmesartan(53 cases,20 mg/d) or amlopipine besylate(50 cases,5 mg/d) for 6 months respectively. The 24 h ambulatory blood pressure monitoring was performed before treatment and at 4,8 weeks of treatment in the two groups. The doses could be doubled or other antihypertensive drugs were added in both groups for controlling the blood pressure. After 8 weeks,BP was con-trolled to normal range in the two groups( P < 0. 05). The baseline echocardiographic findings(left ventricular mass index,LVMI) and microalbuminuria(MA) were compared with those at the end of 6-month follow-up period. Results Lowering and controlling 24 h mean BP levels had no statistically significant difference between two groups. The MBPS change was similar and significantly improved compared with before treatment. LVMI in the olmesartan group was significantly decreased[(118. 5 ± 25. 3)g/m2 vs(108. 3 ± 22. 8)g/m2, P=0. 031 ] ,while the amlodipine group had no change [(117. 6 ± 31. 2)g/m2 vs(112. 8 ± 26. 8)g/m2,P=0. 162 ] . MA was significantly decreased in the two groups. The change in MBPS had no significant correlation with the change in LVMI and MA,24 h and final 2-4 h BP change was closely correlated with the LVMI change. Conclusion Olmesartan medoxomil can effectively control MBPS in primary hypertension,reverses the left ventricular hypertrophy and decreases MA.关键词
奥美沙坦/苯磺酸氨氯地平/高血压/血压晨峰/左室质量指数/尿微量白蛋白Key words
olmesartan/amlodipine besylate/hypertension/morning blood pressure surge/left ventricular mass index/microalbuminuria分类
医药卫生引用本文复制引用
宋琴,董艳梅,颜雪芸,陆瑾钥,郑玉婷..奥美沙坦对高血压患者血压晨峰管理和靶器官保护的临床研究﹡[J].中国药业,2015,(8):14-17,4.基金项目
上海市卫生局科研资助课题（2012年），项目编号20124285。 （）
